Document text
Principal Investigator: PETER LEON COLLINS
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2019
Award: $464,780
Funding agency: National Institute of Allergy and Infectious Diseases
We previously constructed a first-generation construct called HPIV3-EbovZ GP, in which the complete genome of the JS strain of HPIV3 was modified by the addition of the EBOV GP gene in the third gene position, between the HPIV3 P and M genes. The JS strain is thought to be an attenuated HPIV3, based on previous clinical studies, although the basis of this attenuation is unknown. EBOV GP is the sole EBOV virion surface protein, the sole EBOV neutralization antigen, and the major protective antigen. The EBOV GP gene was engineered to have the appropriate HPIV3 transcription signals for it to be expressed as a separate mRNA by the HPIV3 polymerase. HPIV3-EbovZ GP was substantially immunogenic and protective when given to non-human primates by combined intranasal (IN) and intratracheal (IT) administration, even in animals previously infected with HPIV3. However, immunogenicity depended on IT delivery of vaccine: IN delivery alone was insufficient. This suggested that vector expression beyond the upper respiratory tract was necessary for immunogenicity.
We therefore explored delivery of the HPIV3-EbovZ GP construct by the aerosol route in rhesus macaques. The aerosol route was generally more immunogenic and protective than the combined IN/IT route. This induced generally higher serum and mucosal EBOV-specific IgG, IgA, and neutralizing antibody titers, as well as EBOV-specific cellular responses in the lungs, including polyfunctional CD8+ T cells and CD4+ T helper cells that were predominately Th1. In addition, the HPIV3-EbovZ GP vaccine induced more robust cell-mediated and humoral immune responses than an alphavirus vaccine delivered parenterally in parallel. One aerosol dose of HPIV3-EbovZ GP conferred 100% protection to macaques against EBOV challenge.
We developed a second-generation version of this vector, called HPIV3/delHNF/EbovZ-GP, in which the HPIV3 F and HN genes were deleted, leaving EBOV GP as the sole viral surface glycoprotein. A large comparative study in cynomolgus monkeys by our collaborator Alexander Bukreyev at the University of Texas Medical Branch, Galveston, (who made the construct while a Staff Scientist in LID/NIAID) showed that this second-generation version was even more protective than the first-generation even though it was very highly restricted for replication (much more restricted than the first-generation construct).
Nine different pneumovirus or paramyxovirus respiratory viral vectors expressing EBOV GP were compared for immunogenicity and protective efficacy in a guinea pig model for EBOV infection. These vectors included the two HPIV3-based constructs described above (HPIV3-EbovZ-GP and HPIV3/delHNF/EbovZ-GP), two comparable HPIV1-based constructs, and five NDV-based constructs. This study was done primarily by our collaborators at the University of Texas Medical Branch, Galveston. They comprehensively evaluated the antibody responses to the panel of nine respiratory EBOV vaccines given intranasally. Eight of the vaccines were completely protective in guinea pigs, but the vaccines yielded antibody repertoires that differed in a number of their properties, including: avidity towards GP and its fusogenic form, targeting of key antigenic regions, neutralizing antibody specificities, and linear epitope preferences. Competition studies with monoclonal antibodies from human survivors demonstrated that the magnitude of antibodies recognizing the receptor-binding domain and the GP1/GP2 interface at the base of GP correlated with neutralizing titers. These unexpected differences showed that, while an immunogen may determine the general target of an antibody response, distinct vaccine vectors can induce quantitatively and qualitatively different responses that can affect protective efficacy. These data suggest that immune correlates of vaccine protection cannot be generalized for all vaccines against the same pathogen, even if they use the exact same immunogen.
We performed (with clinical collaborators at the Johns Hopkins Bloomberg School of Public Health) an open label phase 1 clinical trial to determine the safety, tolerability, and immunogenicity of HPIV3-EbovZ GP delivered IN in healthy adults in an inpatient setting (NCT025645750), which was intended to be a safety study prior to evaluating aerosol delivery. Ten subjects received two doses (4- to 8-week interval) of 6.0 log10 PFU of vaccine. The first dose was moderately infectious (7/10 subjects shed virus detected by qRT-PCR, mean peak titer 3.8 log10 genomic equivalents/ml, mean duration of shedding 7.9 days). Little shedding was detected after the second dose. A second cohort (n=20) received one of two planned doses of 7.0 log10 PFU of vaccine. Shedding was similar but of shorter duration (mean of 3.7 days). The vaccine was well tolerated, with the exception that asymptomatic ALT elevations were noted in 5 volunteers (3 mild, 2 moderate) in cohort 2 after vaccination and associated with shedding. All resolved by day 28. The study was halted due to these elevations of ALTs, but their significance is unclear. Because of this, this vaccine will not be administered further at this time. Induction of serum antibodies was poor (mucosal antibodies not yet analyzed), but this was expected since, as noted above, we had previously observed that administration by the IN route alone was poorly immunogenic in rhesus monkeys.
We have initiated a Phase 1 study to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/HNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults in an inpatient setting (NCT03462004). Participants are being enrolled sequentially in two cohorts. Participants in Cohort 1 have been randomly assigned to receive two doses of either 6.0 log10 PFU/mL of HPIV3/delHNF/EbovZ-GP vaccine or placebo. The first dose was given on Day 0 and the second dose was given 35 days later. Vaccine replication was evaluated by nasal wash and RT-qPCR and infectivity assays, and serum antibody responses will be measured. As expected, at the 6.0 log10 PFU dose, the HPIV3/HNF/EbovZ-GP vaccine was marginally infectious, and adverse events were generally mild to moderate. The study was deemed safe to proceed to the evaluation of the higher 7.0 log10 PFU dose. Participants in Cohort 2 will be randomly assigned to receive two doses of either 7.0 logPFU/mL of HPIV3/HNF/EbovZ-GP vaccine or placebo on Days 0 and 28.
Terms: <0-11 years old><21+ years old><7S Gamma Globulin><ATGN><Adult><Adult Human><Adverse Experience><Adverse event><Aerosols><Affect><Alpha Virus><Alphavirus><Animals><Antibodies><Antibody Repertoire><Antibody Response><Antibody Specificity><Antibody titer measurement><Antigenic Determinants><Antigens><Assay><Attenuated><Avian Influenza A Virus><Avian Influenza Virus><Avian Orthomyxovirus Type A><Avian Paramyxovirus 1><Avian Paramyxoviruses><Avidity><Avulavirus><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Blood Serum><Bovine Species><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CDC42 Homolog Gene><CDC42-Interacting Protein Gene><CIP4><Cattle><Cavia><Cell Body><Cell Communication and Signaling><Cell Culture Techniques><Cell Signaling><Cell Surface Antigens><Cell Surface Glycoproteins><Cells><Child><Child Youth><Children (0-21)><Chimera><Chimera organism><Clinical><Clinical Research><Clinical Study><Comparative Study><Coronaviridae><Coronavirus><Coronavirus spike protein><Crab-Eating Macaque><Crab-Eating Monkey><Cynomolgus Monkey><Data><Development><Dose><EBOV><EBOV GP><Early-Stage Clinical Trials><Ebola><Ebola Vaccines><Ebola Virus Vaccines><Ebola virus><Ebola virus GP gene product><Ebola virus envelope glycoprotein><Effectiveness><Engineering><Enrollment><Epitopes><Evaluation><Family member><Fowl Plague Virus><G25K Gene><GP Ebola virus><GP Gene><GP1><GP2><GP2 gene><GTP-Binding Protein 1><GTPBP1><GTPBP1 gene><Gene Arrangement><Gene Order><Gene Position><Gene Transcription><General Viruses><Generations><Genes><Genetic Transcription><Genome><Genomics><Glycoprotein 2, Zymogen Granule Membrane><Glycoproteins><Group A Arboviruses><Guinea Pigs><Guinea Pigs Mammals><HPIV1><HPIV3><Hemadsorption Type 2 Virus><Hemadsorption Virus 1><Hemadsorption Virus 2><Hu-mABs><Human><Human Parainfluenza Virus 1><Human Parainfluenza Virus 3><IgA><IgG><Immune><Immune response><Immunes><Immunity><Immunoglobulin A><Immunoglobulin G><Immunologic Surface Markers><Immunological Surface Markers><Immunological response><Infant><Infection><Influenza HA><Influenza Hemagglutinin><Inpatients><Intracellular Communication and Signaling><Intranasal Administration><Intranasal Drug Administration><Lung><Lung Respiratory System><Macaca><Macaca fascicularis><Macaca mulatta><Macaque><Measures><Mediating><Medical><Membrane Glycoproteins><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Messenger RNA><Modeling><Modern Man><Modification><Mucosa><Mucosal Immunity><Mucosal Tissue><Mucous Membrane><Myxovirus pestis galli><NIAID><NIH><Nasal><Nasal Passages Nose><National Institute of Allergy and Infectious Disease><National Institutes of Health><Newcastle disease virus><Non-Polyadenylated RNA><Nose><Para-Influenza Virus Type 1><Para-Influenza Virus Type 3><Paramyxoviridae><Paramyxovirus><Participant><Pathogenicity><Phase 1 Clinical Trials><Phase I Clinical Trials><Phase I Study><Placebos><Pneumovirus><Polymerase><Population><Primates><Primates Mammals><Property><Proteins><Public Health Schools><Pulmonary Body System><Pulmonary Organ System><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA><RNA Expression><RNA Gene Products><Randomized><Respiratory Epithelium><Respiratory System><Respiratory System, Nose, Nasal Passages><Respiratory Tracts><Respiratory tract structure><Rhesus><Rhesus Macaque><Rhesus Monkey><Ribonucleic Acid><Rodent><Rodentia><Rodents Mammals><Route><SARS><Safety><Scientist><Serotyping><Serum><Severe Acute Respiratory Syndrome><Sham Treatment><Signal Transduction><Signal Transduction Systems><Signaling><Structure of respiratory epithelium><Surface Antigens><Surface Glycoproteins><Surface Proteins><Survivors><System><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TRIP10><TRIP10 gene><Testing><Texas><Thyroid Hormone Receptor Interactor 10 Gene><Time><Transcription><United States National Institutes of Health><Universities><Upper respiratory tract><Vaccination><Vaccines><Viral><Viral Diseases><Viral Shedding><Viral Vaccines><Viral Vector><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Virus Shedding><Work><Zymogen Granule Membrane Glycoprotein 2><adulthood><antibody titering><attenuation><avian flu virus><base><biological signal transduction><bird flu virus><bovid><bovine><cell culture><children><childrens'><cohort><conjunctiva><cow><design><designing><develop a vaccine><development of a vaccine><developmental><ebolavirus><enroll><expression vector><flu HA><flu hemagglutinin><host response><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><immunogen><immunogenic><immunogenicity><immunoresponse><influenza virus HA><influenza virus hemagglutinin><mRNA><neutralizing antibody><non-human primate><nonhuman primate><open label><open label study><parainfluenza virus><parainfluenza virus type 1><parainfluenza virus type 3><pathogen><pathogenic virus><phase 1 study><phase 1 trial><phase I protocol><plasmid vaccine><preference><protective efficacy><pulmonary><qRTPCR><randomisation><randomization><randomly assigned><receptor binding><receptor bound><respiratory><response><reverse genetics><safety study><seropositive><sham therapy><tissue tropism><vaccine candidate><vaccine delivery><vaccine development><vaccine formulation><vector><vector vaccine><vector-based vaccine><viral infection><viral multiplication><viral pathogen><viral replication><virus infection><virus multiplication><virus-induced disease><volunteer><youngster>